Cargando…

Linked Clinical Trials – The Development of New Clinical Learning Studies in Parkinson’s Disease Using Screening of Multiple Prospective New Treatments

Finding new therapies for Parkinson’s disease (PD) is a slow process. We assembled an international committee of experts to examine drugs potentially suitable for repurposing to modify PD progression. This committee evaluated multiple drugs currently used, or being developed, in other therapeutic ar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brundin, Patrik, Barker, Roger A., Conn, P. Jeffrey, Dawson, Ted M., Kieburtz, Karl, Lees, Andrew J., Schwarzschild, Michael A., Tanner, Caroline M., Isaacs, Tom, Duffen, Joy, Matthews, Helen, Wyse, Richard K.H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318242/ https://www.ncbi.nlm.nih.gov/pubmed/24018336 http://dx.doi.org/10.3233/JPD-139000

Ejemplares similares

Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience
por: Stott, Simon R. W., et al.
Publicado: (2021)

Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial
por: Simuni, Tanya, et al.
Publicado: (2020)

Are Stem Cell-Based Therapies for Parkinson’s Disease Ready for the Clinic in 2016?
por: Barker, Roger A., et al.
Publicado: (2016)

Parkinson Matters
por: Darweesh, Sirwan K.L., et al.
Publicado: (2018)

Waiting for PARIS—A Biological Target in Search of a Drug: PARIS farnesylation: Considerations in addressing a new biological target for neuroprotection in patients with Parkinson’s disease
por: Wyse, Richard K., et al.
Publicado: (2022)

Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic
por: Sardi, S. Pablo, et al.
Publicado: (2018)

GDNF and Parkinson’s Disease: Where Next? A Summary from a Recent Workshop
por: Barker, Roger A., et al.
Publicado: (2020)

Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson’s Disease: Rationale for Clinical Trial, and Current Progress
por: Carroll, Camille B., et al.
Publicado: (2017)

Parkinson’s Disease: We Care!
por: Bloem, Bastiaan R., et al.
Publicado: (2020)

Nilotinib – Differentiating the Hope from the Hype
por: Wyse, Richard K., et al.
Publicado: (2016)

Immunotherapy in Parkinson’s Disease: Micromanaging Alpha-Synuclein Aggregation
por: George, Sonia, et al.
Publicado: (2015)

People with Parkinson's design clinical trials charter to improve communication about, recruitment to and retention in Parkinson's clinical trials
por: Stamford, Jon, et al.
Publicado: (2015)

A systematic review of the characteristics and validity of monitoring technologies to assess Parkinson’s disease
por: Godinho, Catarina, et al.
Publicado: (2016)

Erratum to: A systematic review of the characteristics and validity of monitoring technologies to assess Parkinson’s disease
por: Godinho, Catarina, et al.
Publicado: (2016)

The Times They Are a-Changin’: Parkinson’s Disease 20 Years from Now
por: Brundin, Patrik, et al.
Publicado: (2018)

Prevalence and Incidence of Nonmotor Symptoms in Individuals with and Without Parkinson's Disease
por: Paracha, Mariam, et al.
Publicado: (2022)

Is COVID-19 a Perfect Storm for Parkinson’s Disease?
por: Brundin, Patrik, et al.
Publicado: (2020)

Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson’s disease
por: Foltynie, Tom, et al.
Publicado: (2023)

Predictors of time to initiation of symptomatic therapy in early Parkinson's disease
por: Simuni, Tanya, et al.
Publicado: (2016)

Is the Enzyme ACMSD a Novel Therapeutic Target in Parkinson’s Disease?
por: Thirtamara-Rajamani, Keerthi, et al.
Publicado: (2017)

Editorial: Targeting α-Synuclein in Parkinson's Disease and Multiple System Atrophy
por: Fellner, Lisa, et al.
Publicado: (2022)

Enrichment of risk SNPs in regulatory regions implicate diverse tissues in Parkinson’s disease etiology
por: Coetzee, Simon G., et al.
Publicado: (2016)

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort
por: Simuni, Tanya, et al.
Publicado: (2018)

A New Approach to the Development of Disease‐Modifying Therapies for PD; Fighting Another Pandemic
por: Kieburtz, Karl, et al.
Publicado: (2020)

What’s to like about the prion-like hypothesis for the spreading of aggregated α-synuclein in Parkinson disease?
por: Dunning, Christopher J.R., et al.
Publicado: (2013)

Precision medicine in Parkinson’s disease patients with LRRK2 and GBA risk variants – Let’s get even more personal
por: von Linstow, Christian U., et al.
Publicado: (2020)

Linking α-synuclein-induced synaptopathy and neural network dysfunction in early Parkinson’s disease
por: Kulkarni, Aishwarya S, et al.
Publicado: (2022)

Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort
por: Simuni, Tanya, et al.
Publicado: (2018)

The clinical applicability of a new automatic sugar analyser
por: Dörner, Klaus, et al.
Publicado: (1981)

Trichloroethylene: An Invisible Cause of Parkinson’s Disease?
por: Dorsey, E. Ray, et al.
Publicado: (2023)

Decreased Risk of Parkinson’s Disease After Rheumatoid Arthritis Diagnosis: A Nested Case-Control Study with Matched Cases and Controls
por: Bacelis, Jonas, et al.
Publicado: (2021)

Advocacy Recruiting for Huntington’s Disease Clinical Trials
por: Goodman, LaVonne, et al.
Publicado: (2011)

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020
por: McFarthing, Kevin, et al.
Publicado: (2020)

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update
por: McFarthing, Kevin, et al.
Publicado: (2021)

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update
por: McFarthing, Kevin, et al.
Publicado: (2022)

Chasing Protection in Parkinson’s Disease: Does Exercise Reduce Risk and Progression?
por: Crotty, Grace F., et al.
Publicado: (2020)

Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures
por: Chahine, Lana M., et al.
Publicado: (2019)

Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases
por: Malek, Naveed, et al.
Publicado: (2017)

Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease
por: Heilman, Patrick L., et al.
Publicado: (2020)

Does Developmental Variability in the Number of Midbrain Dopamine Neurons Affect Individual Risk for Sporadic Parkinson’s Disease?
por: von Linstow, Christian U., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9272odhq1rs8rv5aua0qceois2